English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/245439
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial

AuthorsKoller, Dora; Almenara, Susana; Mejía, Gina; Saiz-Rodríguez, Miriam; Zubiaur, Pablo; Román, Manuel; Ochoa, Dolores; Wojnicz, Aneta; Martín, Samuel; Romero-Palacián, Daniel; Navares-Gómez, Marcos; Abad-Santos, Francisco
KeywordsAripiprazole
Cardiovascular effects
Olanzapine
Pharmacogenetics
Safety
Issue DateJan-2021
PublisherJohn Wiley & Sons
CitationHuman Psychopharmacology - Clinical and Experimental 36(1): 1-12 (2021)
Abstract[Objective] To assess adverse events (AEs) and safety of aripiprazole (ARI) and olanzapine (OLA) treatment. [Methods] Twenty-four healthy volunteers receiving five daily oral doses of 10 mg ARI and 5 mg OLA in a crossover clinical trial were genotyped for 46 polymorphisms in 14 genes by qPCR. Drug plasma concentrations were measured by high-performance liquid chromatography tandem mass spectrometry. Blood pressure (BP) and 12-lead electrocardiogram were measured in supine position. AEs were also recorded. [Results] ARI decreased diastolic BP on the first day and decreased QTc on the third and fifth day. OLA had a systolic and diastolic BP, heart rate and QTc lowering effect on the first day. Polymorphisms in ADRA2A, COMT, DRD3 and HTR2A genes were significantly associated to these changes. The most frequent adverse drug reactions (ADRs) to ARI were somnolence, headache, insomnia, dizziness, restlessness, palpitations, akathisia and nausea while were somnolence, dizziness, asthenia, constipation, dry mouth, headache and nausea to OLA. Additionally, HTR2A, HTR2C, DRD2, DRD3, OPRM1, UGT1A1 and CYP1A2 polymorphisms had a role in the development of ADRs. [Conclusions] OLA induced more cardiovascular changes; however, more ADRs were registered to ARI. In addition, some polymorphisms may explain the difference in the incidence of these effects among subjects.
Publisher version (URL)https://doi.org/10.1002/hup.2761
URIhttp://hdl.handle.net/10261/245439
DOIhttp://dx.doi.org/10.1002/hup.2761
ISSN0885-6222
E-ISSN1099-1077
ReferencesKoller, Dora; Almenara, Susana; Mejía, Gina; Saiz-Rodríguez, Miriam; Zubiaur, Pablo; Román, Manuel; Ochoa, Dolores; Wojnicz, Aneta; Martín, Samuel; Romero-Palacián, Daniel; Navares-Gómez, Marcos; Abad-Santos, Francisco (2021) "Dataset related to article: Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial [Dataset]", http://dx.doi.org/10.20350/digitalCSIC/13929
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.